Literature DB >> 23850894

Insights in the chemical components of liposomes responsible for P-glycoprotein inhibition.

Joanna Kopecka1, Giuseppina Salzano1, Ivana Campia1, Sara Lusa2, Dario Ghigo1, Giuseppe De Rosa3, Chiara Riganti4.   

Abstract

In this work we investigated how the surface charge and the presence of polyethylene glycol (PEG) on liposome carriers affect the delivery of the encapsulated doxorubicin in P-glycoprotein (Pgp)-overexpressing cells. We found that neutral net charge was critical to favour the liposome uptake and decrease the Vmax of doxorubicin efflux. PEG-coating was necessary to increase the Km of doxorubicin for Pgp. In particular the PEGylated phospholipid present in neutral liposomes, i.e. PEGylated distearoyl-phosphatidylethanolamine (DSPE-PEG), was a Pgp allosteric inhibitor, increased doxorubicin Km and inhibited Pgp ATPase activity. Site-directed mutagenesis experiments suggested that the domain centred around glycine 185 of Pgp was necessary for these inhibitory properties of DSPE-PEG and PEGylated neutral liposomes. We conclude that both surface charge and PEGylation must be considered to optimize the doxorubicin delivery within chemoresistant cells. DSPE-PEG-enriched particles may represent promising tools for therapeutic and diagnostic applications in tissues with high levels of Pgp. FROM THE CLINICAL EDITOR: These authors investigated how surface charge and PEGylation of liposome carriers affect the delivery of encapsulated doxorubicin to Pgp-overexpressing cells, concluding that both factors need to be considered in order to optimize doxorubicin delivery to chemoresistant cells.
© 2013.

Entities:  

Keywords:  1,2-dioleoyloxy-3-trimethylammoniumpropanchloride; 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-glycerol; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; BCRP; Chemoresistance; DOTAP; DPPC; DPPG; DSPE-PEG; Doxorubicin; Liposome; MRPs; P-glycoprotein; PEG; PEGylated distearoyl-phosphatidylethanolamine; Pgp; Polyethylene glycol; breast cancer resistance protein; multidrug-resistance related proteins; polyethylene glycol

Mesh:

Substances:

Year:  2013        PMID: 23850894     DOI: 10.1016/j.nano.2013.06.013

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  13 in total

1.  In vivo Functional Evaluation of Increased Brain Delivery of the Opioid Peptide DAMGO by Glutathione-PEGylated Liposomes.

Authors:  Annika Lindqvist; Jaap Rip; Joan van Kregten; Pieter J Gaillard; Margareta Hammarlund-Udenaes
Journal:  Pharm Res       Date:  2015-08-15       Impact factor: 4.200

2.  Long-Circulating Amphiphilic Doxorubicin for Tumor Mitochondria-Specific Targeting.

Authors:  Jingchao Xi; Meng Li; Benxin Jing; Myunggi An; Chunsong Yu; Cameron B Pinnock; Yingxi Zhu; Mai T Lam; Haipeng Liu
Journal:  ACS Appl Mater Interfaces       Date:  2018-12-06       Impact factor: 9.229

3.  Remarkable response in 2 cases of Advanced Poorly Differentiated Thyroid Carcinoma with liposomal doxorubicin plus cisplatin.

Authors:  Haiyan Yang; Zhongjian Chen; Meijuan Wu; Tao Lei; Haifeng Yu; Minghua Ge
Journal:  Cancer Biol Ther       Date:  2016-06-02       Impact factor: 4.742

4.  Mixed polyethylene glycol-modified breviscapine-loaded solid lipid nanoparticles for improved brain bioavailability: preparation, characterization, and in vivo cerebral microdialysis evaluation in adult Sprague Dawley rats.

Authors:  Zhidong Liu; Chukwunweike Ikechukwu Okeke; Li Zhang; Hainan Zhao; Jiawei Li; Mike Okweesi Aggrey; Nan Li; Xiujun Guo; Xiaochen Pang; Lili Fan; Lili Guo
Journal:  AAPS PharmSciTech       Date:  2014-01-31       Impact factor: 3.246

5.  NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function.

Authors:  Shunan Ye; Jianming Zhang; Jacson Shen; Yan Gao; Ying Li; Edwin Choy; Gregory Cote; David Harmon; Henry Mankin; Nathanael S Gray; Francis J Hornicek; Zhenfeng Duan
Journal:  Br J Pharmacol       Date:  2016-01-15       Impact factor: 8.739

6.  Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy.

Authors:  Josimar O Eloy; Raquel Petrilli; José Fernando Topan; Heriton Marcelo Ribeiro Antonio; Juliana Palma Abriata Barcellos; Deise L Chesca; Luciano Neder Serafini; Daniel G Tiezzi; Robert J Lee; Juliana Maldonado Marchetti
Journal:  Colloids Surf B Biointerfaces       Date:  2016-01-22       Impact factor: 5.268

7.  Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells.

Authors:  Joanna Kopecka; Ivana Campia; Andrea Jacobs; Andreas P Frei; Dario Ghigo; Bernd Wollscheid; Chiara Riganti
Journal:  Oncotarget       Date:  2015-03-30

8.  Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells.

Authors:  Joanna Kopecka; Stefania Porto; Sara Lusa; Elena Gazzano; Giuseppina Salzano; Antonio Giordano; Vincenzo Desiderio; Dario Ghigo; Michele Caraglia; Giuseppe De Rosa; Chiara Riganti
Journal:  Oncotarget       Date:  2015-10-13

9.  The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells.

Authors:  Barbara Castella; Joanna Kopecka; Patrizia Sciancalepore; Giorgia Mandili; Myriam Foglietta; Nico Mitro; Donatella Caruso; Francesco Novelli; Chiara Riganti; Massimo Massaia
Journal:  Nat Commun       Date:  2017-06-05       Impact factor: 14.919

10.  Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.

Authors:  Iris C Salaroglio; Elena Gazzano; Ahmad Abdullrahman; Eleonora Mungo; Barbara Castella; Gamal Eldein Fathy Abd-Ellatef Abd-Elrahman; Massimo Massaia; Massimo Donadelli; Menachem Rubinstein; Chiara Riganti; Joanna Kopecka
Journal:  J Exp Clin Cancer Res       Date:  2018-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.